PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

SR One raises $600m for second venture fund

SR One, a transatlantic life sciences investment firm, has closed its second fund at over $600 million, substantially exceeding its target of $500 million. Fund II is the second fund since SR One spun out from GlaxoSmithKline in 2020 to form a fully independent investment firm. 

SR One, a transatlantic life sciences investment firm, has closed its second fund (Fund II) at over $600 million, substantially exceeding its target of $500 million. Fund II is the second fund since SR One spun out from GlaxoSmithKline (GSK) in 2020 to form a fully independent investment firm. 

The diverse investor base of existing and new limited partners includes endowments, foundations, pharmaceutical companies, pension funds, sovereign wealth funds, and family offices.
  
With Fund II, SR One says it will continue to invest in biotechnology companies that :”have the potential to address significant gaps in the current treatment landscape”. SR One’s investment strategy focuses on providing financial and direct operational support to its portfolio companies.
  
Kirkland & Ellis acted as counsel to SR One for the fundraise. 
 

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured